EP
BCYC

Eversept Partners’s Bicycle Therapeutics BCYC Stock Holding History

Eversept Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$809K Hold
190,715
– – 0.04% 109
2026
Q1 		$885K Buy
190,715
+11,800
+7% +$67.4K 0.05% 112
2025
Q4 		$1.27M Sell
178,915
-15,525
-8% -$114K 0.06% 96
2025
Q3 		$1.5M Sell
194,440
-17,029
-8% -$129K 0.1% 74
2025
Q2 		$1.47M Buy
+211,469
New +$1.68M 0.14% 57

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Eversept Partners's BCYC Position: Q2 2026 in Review

Eversept Partners held its Bicycle Therapeutics (BCYC) position steady in Q2 2026 at 190,715 shares worth $809K. The position accounts for 0.04% of the portfolio, ranked #109.

Eversept Partners first reported a position in BCYC in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.5M in Q3 2025. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Eversept Partners held 190,715 shares of Bicycle Therapeutics worth $809K as of Q2 2026.
  • Eversept Partners left its Bicycle Therapeutics share count unchanged in Q2 2026.
  • Bicycle Therapeutics made up 0.04% of Eversept Partners's portfolio in Q2 2026, its #109 holding.
  • Eversept Partners first reported a position in Bicycle Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Eversept Partners's Bicycle Therapeutics position peaked at $1.5M in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.